ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 123.94

Change

+2.44 (+2.01)%

Market Cap

USD 215.24B

Volume

4.44M

Average Target Price

USD 128.31 (+3.52%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MDT Medtronic plc

+1.95 (+1.57%)

USD167.03B 54.85 29.62
SYK Stryker Corporation

+4.56 (+1.81%)

USD94.94B 60.07 34.83
BSX Boston Scientific Corporation

+1.19 (+3.00%)

USD56.35B 15.10 45.31
EW Edwards Lifesciences Corporati..

+1.75 (+2.03%)

USD53.65B 66.35 50.77
ZBH Zimmer Biomet Holdings, Inc

+3.45 (+2.05%)

USD35.06B 814.82 43.93
BIO Bio-Rad Laboratories, Inc

+12.68 (+2.07%)

USD18.41B 4.89 3.40
BIO-B Bio-Rad Laboratories, Inc

N/A

USD18.01B 4.76 3.40
SNN Smith & Nephew plc

+0.60 (+1.53%)

USD16.99B 38.18 21.28
PEN Penumbra, Inc

+8.10 (+2.91%)

USD10.14B 813.79 490.23
GMED Globus Medical, Inc

+0.72 (+1.04%)

USD6.87B 68.25 35.07

ETFs Containing ABT

Symbol Name Weight Mer Price(Change) Market Cap
BSCL Invesco BulletShares 2021.. 0.00 % 0.10 %

-0.01 (-0.05%)

USD1.88B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.61 (+1.77%)

USD0.19B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
DRFG:CA Desjardins RI Global Mult.. 0.00 % 0.60 %

+0.17 (+0.70%)

USD0.01B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

+0.13 (+1.59%)

N/A
FHI-B:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

N/A
HLAL Wahed FTSE USA Shariah ET.. 0.00 % 0.50 %

+0.36 (+0.99%)

USD0.08B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+12.50 (+1.93%)

USD1.69B
ISDU:LSE iShares MSCI USA Islamic .. 0.00 % 0.50 %

+0.26 (+0.47%)

USD0.09B
ISDW:LSE iShares MSCI World Islami.. 0.00 % 0.60 %

+0.25 (+0.60%)

USD0.19B
ISUS:LSE iShares MSCI USA Islamic .. 0.00 % 0.50 %

+21.00 (+0.53%)

USD0.13B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.16 (+1.83%)

USD1.39B
WHEA:LSE SPDR MSCI World Health Ca.. 0.00 % 0.30 %

+0.77 (+1.51%)

USD0.31B
BDIV:CA Brompton Global Dividend .. 0.00 % 0.75 %

N/A

USD0.06B
XDWH:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.25 %

+0.69 (+1.55%)

USD1.10B
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

+68.50 (+1.94%)

USD0.77B
XUHC:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.12 %

+0.89 (+1.83%)

USD0.47B
OPEN:F iShares Thomson Reuters I.. 0.00 % 0.25 %

+0.01 (+0.11%)

USD5.05M
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.13 (+1.69%)

USD1.40B
XDWH:F Xtrackers (IE) Plc - Xtra.. 0.00 % 0.25 %

+0.55 (+1.49%)

USD1.10B
ZPDH:F SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.48 (+1.66%)

USD0.20B
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.15 (+1.95%)

USD1.40B
XDWH:XETRA Xtrackers (IE) Plc - Xtra.. 0.00 % 0.25 %

+0.63 (+1.71%)

USD1.39B
XUHC:XETRA Xtrackers (IE) Plc - Xtra.. 0.00 % 0.12 %

+0.79 (+1.94%)

USD0.47B
RWDC Direxion MSCI Defensives .. 0.00 % 0.46 %

N/A

USD7.11M
FHI:CA CI First Asset Health Car.. 0.00 % 0.65 %

+0.14 (+1.26%)

USD0.15B
CURE Direxion Daily Healthcare.. 0.00 % 1.01 %

+4.60 (+5.29%)

USD0.13B
SPHQ Invesco S&P 500 Quality E.. 0.00 % 0.15 %

+0.64 (+1.40%)

USD2.52B
CWS AdvisorShares Focused Equ.. 0.00 % 0.77 %

+0.53 (+1.16%)

USD0.02B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

+1.01 (+1.69%)

USD2.52B
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

+7.74 (+2.25%)

USD8.66B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+1.12 (+1.43%)

USD2.64B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

+4.69 (+1.83%)

USD2.50B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

+0.71 (+1.58%)

USD0.05B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.66 (+0.84%)

USD0.36B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.29 (-3.38%)

USD1.51M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.29 (-3.38%)

USD1.51M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+2.87 (+3.48%)

USD0.11B
SPMO Invesco S&P 500 Momentum .. 0.00 % 0.13 %

+1.01 (+1.80%)

USD0.08B
HIG:CA Brompton Global Healthcar.. 0.00 % 0.75 %

+0.21 (+2.16%)

USD0.05B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+4.30 (+1.85%)

USD16.24B
VIG Vanguard Dividend Appreci.. 0.00 % 0.06 %

+1.51 (+1.00%)

USD67.23B
XHC:CA iShares Global Healthcare.. 0.00 % 0.63 %

+0.81 (+1.35%)

USD0.45B
XLV Health Care Select Sector.. 0.00 % 0.12 %

+2.03 (+1.71%)

USD24.05B
YLD Principal Active Income E.. 0.00 % 0.49 %

+0.07 (+0.18%)

USD0.23B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

+0.12 (+1.51%)

USD0.33B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

+0.31 (+1.46%)

USD0.01B
JMIN JPMorgan U.S. Minimum Vol.. 0.00 % 0.12 %

+0.39 (+1.13%)

USD0.02B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

+0.10 (+0.39%)

USD0.02B
EVSTC Eaton Vance Stock NextSha.. 0.00 % 0.65 %

N/A

USD7.39M
ACT AdvisorShares Vice ETF 0.00 % 0.99 %

N/A

USD9.13M
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.56 (+1.93%)

USD0.20B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.20% 64% D 65% D
Dividend Return 0.82% 83% B 46% F
Total Return 14.02% 68% D+ 65% D
Trailing 12 Months  
Capital Gain 29.10% 36% F 35% F
Dividend Return 1.69% 67% D+ 21% F
Total Return 30.79% 36% F 33% F
Trailing 5 Years  
Capital Gain 185.51% 69% D+ 91% A-
Dividend Return 14.56% 100% A+ 49% F
Total Return 200.07% 75% C 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 26.89% 60% D- 91% A-
Dividend Return 2.06% 86% B 50% F
Total Return 28.95% 68% D+ 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.14% 96% A 75% C
Risk Adjusted Return 238.39% 100% A+ 100% A+
Market Capitalization 215.24B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 48.54 59% F 16% F
Price/Book Ratio 6.65 35% F 16% F
Price / Cash Flow Ratio 27.24 42% F 13% F
EV/EBITDA 26.06 55% F 23% F
Management Effectiveness  
Return on Equity 13.91% 88% B+ 79% C+
Return on Invested Capital 9.65% 89% B+ 75% C
Return on Assets 4.94% 89% B+ 79% C+
Debt to Equity Ratio 56.51% 38% F 59% F
Technical Ratios  
Short Ratio 2.61 52% F 34% F
Short Percent 0.79% 92% A- 86% B
Beta 0.70 85% B 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector